---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-172653"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:23:46.584431+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Catalyst expands Board to 7 with appointment of Dr. Daniel Curran

## Summary
- Board increased from 6 to 7 members; Dr. Curran appointed effective immediately.
- Curran brings 25+ years pharma experience; served as SVP at Takeda Rare Genetics (2019-2023).
- Currently CEO of Timberlyne Therapeutics and Managing Partner at Mountainfield Venture Partners.

## SEC filing metadata
- accession: 0001193125-25-172653
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525172653/0001193125-25-172653-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525172653/d17349d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-172653
- JSON: https://secwatch.observer/filing/0001193125-25-172653.json
- Plain text: https://secwatch.observer/filing/0001193125-25-172653.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.